| 2017-07-17 07:09:31|
TRIL 07:09 07/17 07/17/17
Trillium Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Trillium Therapeutics with a Buy rating and $7 price target. The analyst estimates that Trillium's lead product, TTI-621, which is currently being evaluated in Phase 1 and Phase 1b clinical studies, could be the first marketed CD47-targeting therapy and can generate peak sales of C$1.4B for hematologic and solid tumors.